Article | REF: N4965 V1

Mineral adjuvants for vaccination in oncology

Author: Patrick FRAYSSINET

Publication date: April 10, 2014

You do not have access to this resource.
Click here to request your free trial access!

Already subscribed? Log in!


Overview

Français

ABSTRACT

Immunotherapy and more particularly vaccines are gaining a role among the various drugs available in oncology. A therapeutic vaccine is composed of one or several proteic or glycoproteic antigens against which the immune system will fight and an adjuvant which amplify the immune response against the former molecules. Today among them two kinds of mineral adjuvants are available: aluminum containing adjuvants, and calcium phosphate.. Their characteristics and mode of action is described hereby.

Read this article from a comprehensive knowledge base, updated and supplemented with articles reviewed by scientific committees.

Read the article

AUTHOR

 INTRODUCTION

Over the course of the 20th century, vaccines have become the most effective tool for preventing infectious diseases and allergies. They are used to prevent two of the most common cancers of infectious origin in humans: liver cancer and uterine cancer. Other cancers are not of infectious origin, but therapeutic vaccines are currently being studied in oncology to treat cancers that have already occurred. These vaccines are possible because cancer cells produce abnormal proteins which, under normal conditions, trigger an immune response that eliminates these cells.

Treating cancer by stimulating the immune system is not a new idea. Very advanced cancers that regressed spontaneously have been known since ancient times. At the beginning of the 20th century, William Cole, an American surgeon, injected bacterial extracts into connective tissue cancer tumors (sarcoma), triggering a non-specific inflammatory reaction in the tumor cells with very significant hyperthermia, and achieving results largely comparable to those obtained today with heavy chemotherapy. More recently, cancers of the bladder epithelium have been washed with a solution containing inactivated bacillus Koch (BCG) to trigger a cellular immune response against the cancer cells.

Today, many techniques exist to activate the immune system, many of them involving tissue engineering techniques. We will focus on classical vaccine techniques, namely the injection of one or more proteins or glycoproteins specific to the agent to be eliminated, accompanied by an adjuvant agent that amplifies the immune response against the preceding compounds. In this article, we describe the contribution of inorganic vaccine adjuvants to cancer immunotherapy.

You do not have access to this resource.

Exclusive to subscribers. 97% yet to be discovered!

You do not have access to this resource.
Click here to request your free trial access!

Already subscribed? Log in!


The Ultimate Scientific and Technical Reference

A Comprehensive Knowledge Base, with over 1,200 authors and 100 scientific advisors
+ More than 10,000 articles and 1,000 how-to sheets, over 800 new or updated articles every year
From design to prototyping, right through to industrialization, the reference for securing the development of your industrial projects

KEYWORDS

state of the art   |   Adjuvants   |   cancer vaccine   |   health   |  


This article is included in

Healthcare technologies

This offer includes:

Knowledge Base

Updated and enriched with articles validated by our scientific committees

Services

A set of exclusive tools to complement the resources

Practical Path

Operational and didactic, to guarantee the acquisition of transversal skills

Doc & Quiz

Interactive articles with quizzes, for constructive reading

Subscribe now!

Ongoing reading
Mineral adjuvants for oncology vaccines